Progyny, Inc. (NASDAQ:PGNY) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC cut its stake in Progyny, Inc. (NASDAQ:PGNYGet Rating) by 80.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,194 shares of the company’s stock after selling 69,820 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Progyny were worth $637,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Progyny by 0.8% in the first quarter. Vanguard Group Inc. now owns 6,525,283 shares of the company’s stock worth $335,399,000 after buying an additional 49,779 shares during the period. Clearbridge Investments LLC increased its position in Progyny by 13.3% in the second quarter. Clearbridge Investments LLC now owns 3,652,887 shares of the company’s stock worth $106,116,000 after buying an additional 429,385 shares during the period. State Street Corp increased its position in Progyny by 4.9% in the second quarter. State Street Corp now owns 2,176,636 shares of the company’s stock worth $63,231,000 after buying an additional 100,958 shares during the period. Thrivent Financial for Lutherans grew its stake in shares of Progyny by 74.6% in the second quarter. Thrivent Financial for Lutherans now owns 2,171,417 shares of the company’s stock worth $63,080,000 after purchasing an additional 927,692 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Progyny by 8.6% in the second quarter. JPMorgan Chase & Co. now owns 2,128,580 shares of the company’s stock worth $61,835,000 after purchasing an additional 168,719 shares in the last quarter. 86.12% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Progyny

In related news, Director Norman Payson sold 6,617 shares of the stock in a transaction on Wednesday, December 21st. The stock was sold at an average price of $31.65, for a total value of $209,428.05. Following the completion of the transaction, the director now owns 279,063 shares in the company, valued at approximately $8,832,343.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Norman Payson sold 6,617 shares of the stock in a transaction dated Wednesday, December 21st. The stock was sold at an average price of $31.65, for a total value of $209,428.05. Following the completion of the sale, the director now directly owns 279,063 shares of the company’s stock, valued at approximately $8,832,343.95. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Peter Anevski sold 34,385 shares of the stock in a transaction dated Tuesday, October 25th. The stock was sold at an average price of $39.76, for a total value of $1,367,147.60. Following the completion of the sale, the chief executive officer now directly owns 250,445 shares of the company’s stock, valued at $9,957,693.20. The disclosure for this sale can be found here. Insiders sold 123,966 shares of company stock worth $4,787,473 in the last quarter. 14.00% of the stock is owned by company insiders.

Progyny Stock Down 0.8 %

Shares of PGNY stock opened at $33.02 on Monday. The stock has a 50-day simple moving average of $32.68 and a 200 day simple moving average of $36.37. Progyny, Inc. has a fifty-two week low of $25.67 and a fifty-two week high of $53.10. The stock has a market capitalization of $3.07 billion, a P/E ratio of 78.62, a P/E/G ratio of 4.22 and a beta of 1.59.

Progyny (NASDAQ:PGNYGet Rating) last released its quarterly earnings results on Thursday, November 3rd. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.08. Progyny had a return on equity of 14.14% and a net margin of 6.00%. The business had revenue of $205.37 million during the quarter, compared to analyst estimates of $194.41 million. On average, sell-side analysts anticipate that Progyny, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on PGNY. KeyCorp decreased their price target on Progyny from $55.00 to $45.00 and set an “overweight” rating for the company in a research note on Monday, December 19th. TheStreet raised Progyny from a “d+” rating to a “c” rating in a research note on Monday, October 24th. SVB Leerink reissued a “market perform” rating and issued a $34.00 price target (down previously from $59.00) on shares of Progyny in a research note on Thursday, January 5th. Finally, JPMorgan Chase & Co. decreased their price target on Progyny from $78.00 to $62.00 and set an “overweight” rating for the company in a research note on Friday, November 18th. One analyst has rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Progyny currently has an average rating of “Moderate Buy” and an average price target of $49.25.

Progyny Profile

(Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Articles

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNYGet Rating).

Institutional Ownership by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.